Cytokeratin 10 and cytokeratin 19: Predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3850-3859

  Xin RongYang, ^a   Xu, Yang ^a   Shi, Guo Ming ^a   Fan, Jia ^a,c   Zhou, Jian ^a   Ji, Yuan ^a   Sun, Hui Chuan ^a   Qiu, Shuang Jian ^a   Yu, Bing ^b   Gao, Qiang ^a   He, Yi Zhou ^a   Qin, Weng Zhen ^a   Chen, Rong Xin ^a   Yang, Guo Huan ^a   Wu, Bing ^a   Lu, Qing ^a   Wu, Zhi Quan ^a   Tang, Zhao You ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYTOKERATIN 20; CYTOKERATIN 9; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; TUMOR MARKER; CYTOKERATIN 10; CYTOKERATIN 19;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TISSUE MICROARRAY; WESTERN BLOTTING; AGED; COHORT ANALYSIS; FOLLOW UP; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; POSTOPERATIVE PERIOD; SURVIVAL; TUMOR CELL LINE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-10; KERATIN-19; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 52449093970     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4338     Document Type: Article

References (50)

1. 1.Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. 2.Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187-96.
3. 3.Yang Y, Nagano H, Ota H, et al. Patterns and clinico-pathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007;141:196-202.
4. 4.Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
5. 5.Qin LX.Tang ZY. Recent progress in predictive bio-markers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130:497-513.
6. 6.Gao Q, Qiu SJ, Fan J. et al. Intratumoral balance of regulatory and cytotoxic T-cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
7. 7.Hsu YC, Fu HH. Jeng YM, Lee PH.Yang SD. Proline- directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol 2006;24:3780-8.
8. 8.Lopez JB. Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev 2005; 26:65-79
9. 9.Peng SY, Chen WJ, Lai PL, et al. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53, and β-catenin mutations Int J Cancer 2004;112:44-50.
10. 10.Arias LF, Blanco J, Hernandez S, Bocardo G, Gonzalez L. Immunohistochemical profile and clinical features of mucinous tubular and spindle renal cell carcinoma. Actas Urol Esp 2006.30 649-54
11. Apaydin R, Gurbuz Y. Bayramgurler D, Bilen N Cyto- keratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis an immunohistochemical study. Amyloid 2005:12 41-7.
12. 12.Kim MA, Lee HS, Yang HK, Kim WH Cytokeratm expression profile in gastric carcinomas. Hum Pathol 2004:35:576-81.
13. 13.Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002:41 365 6
14. 14.Hendrix MJ, Seftor EA, Chu YW. Trevor KT. Seftor RE Role of intermediate filaments in migration, invasion, and metastasis. Cancer Metastasis Rev 1996:15:507-25.
15. 15.D'ErricoA. Baccarini P, Fiorentino M. etal Histogenesis of primary liver carcinomas, strengths and weaknesses of cytokeratin profile and albumin mRNA detection. Hum Pathol 1996;27:599-604.
16. 16.Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006;14:266-72.
17. 17.Dai Z, LiuYK, Cui JF, et al. Identification and analysis of altered α1,6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics 2006;6:5857-67.
18. 18.Ding SJ, Li Y, Shao XX, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004;4:982-94.
19. 19.Ding SJ, Li YTan YX, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81.
20. 20.Uenishi T, Kubo S.Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003:94:851-7.
21. 21.Li Y Tang ZY.Tian B, et al. Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients. J Cancer Res Clin Oncol 2006;132:515-20.
22. 22.Durnez A, Verslype C, Nevens F, et al. The clinico- pathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology 2006;49:138-51.
23. 23.Li Y, Tian B.Yang J, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004;130:460-8.
24. 24.Cui JF, Liu YK, Zhang LJ, et al. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 2006;6:5953-61.
25. 25.Wu X, Jia HL.Wang YF, etal. HTPAP gene on chromosome 8p is a candidate metastasis suppressor for human hepatocellular carcinoma. Oncogene 2006;25:1832-40.
26. 26.Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques 2004;36:98-105.
27. 27.Shah SA, Cleary SP.Wei AC, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330-9.
28. 28.Ishak KG, Anthony PP, Sobin LH. Nonepithelial tumors. In: Ishak KG, editor. Histological typing of tumors of the liver. World Health Organization International Classification of tumors. Berlin: Springer; 1994. p. 22-7.
29. 29.Wittekind C. Pitfalls in the classification of liver tumors. Pathologe 2006;27:289-93.
30. 30.Peng DJ, Sun J, Wang YZ, et al. Inhibition of hepa-tocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther 2007;14:66-73.
31. 31.Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:293-301.
32. 32.FilliesT, Werkmeister R, Packeisen J, etal. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity. BMC Cancer 2006:13:10.
33. 33.Kurokawa I, Urakawa Y, SenbaY et al. Keratin profiles may differ between intraepidermal and intradermal invasive eccrine porocarcinoma. Oncol Rep 2006;16:473-7.
34. 34.Yang XJ, Lecksell K, Gaudin P, Ji E. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999;23:147-52.
35. 35.Wang GF, Lai MD.Yang RR, et al. Histological types and significance of bronchial epithelial dysplasia. Mod Pathol 2006;19:429-37.
36. 36.Tamura N, linuma H.Takada T. Prospective study of the quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes to predict peritoneal recurrence in gastric carcinoma patients. Oncol Rep 2007;17:667-72.
37. 37.Gretschel S, Schick C, Schneider U, et al. Prognostic value of cytokeratin-positive bone marrow cells of gastric cancer patients. Ann Surg Oncol 2007;14:373-80.
38. 38.Tsubokawa F, NishisakaT, Takeshima Y, Inai K. Heterogeneity of expression of cytokeratin subtypes in squamous cell carcinoma of the lung: with special reference to CK14 overexpression in cancer of high- proliferative and lymphogenous metastatic potential. Pathol Int 2002;52:286-93.
39. 39.Ohkawa T, Naomoto Y.Takaoka M,et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 2004:84:1289-304.
40. 40.Kuo T. Cytokeratin profiles of the thymus and thymomas: histogenetic correlations and proposal for a histological classification of thymomas. Histopatholo- gy 2000;36:403-14.
41. 41.Zhao HW, Li LJ, Xie WY. Clinic significance of morphometric study on squamous cell carcinoma of floor of mouth. Hua Xi Kou Qiang Yi Xue Za Zhi 2004;22:220-3.
42. 42.Maeda T, Takenaka K.Taguchi K, et al. Adenosqua- mous carcinoma of the liver: clinicopathologic characteristics and cytokeratin profile. Cancer 1997;80:364-71.
43. 43.Park JH, Koh KC, Choi MS, et al. Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg Pathol 2006;192:29-33.
44. 44.Poon RT, Ng IO, Fan ST, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001;19:3037-44.
45. 45.Chovanec M, Plzak J, Betka J, et al. Comparative analysis of α2,3/2,6-linked N-acetylneuraminic acid and cytokeratin expression in head and neck squamous cell carcinoma. Oncol Rep 2004;12:297-301.
46. 46.Shirakawa Y NaomotoY Kimura M, et al. Topological analysis of p21WAF1/CIP1 expression in esophageal squamous dysplasia. Clin Cancer Res 2000;6:541 -50.
47. 47.van Eyken P, Sciot R, van Damme B, de Wolf- Peeters C, Desmet VJ. Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepato-cytes, bile ducts, and acinar gradient. Virchows Arch A Pathol Anat Hist1987;412:63-72.
48. 48.Biermann H, Rauterberg EW. Expression of fetal cytokeratins in epidermal cells and colloid bodies in lichen planus. J Cutan Pathol 1998;25:35-43.
49. 49.Mandys V, Lukas K, Revoltella R. Different patterns of cytokeratin expression in Barrett's esophagus: what is beyond? Pathol Res Pract 2003;199:581-7.
50. 50.El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.